Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
7,059,412
-
Share change
-
+1,257,126
-
Total reported value
-
$24,419,460
-
Price per share
-
$3.46
-
Number of holders
-
31
-
Value change
-
+$4,270,544
-
Number of buys
-
13
-
Number of sells
-
10
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q1 2020
As of 31 Mar 2020,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,059,412 shares.
The largest 10 holders included
BVF INC/IL, Nantahala Capital Management, LLC, Ibex Investors LLC, Vivo Capital, LLC, 683 Capital Management, LLC, RAYMOND JAMES & ASSOCIATES, BAKER BROS. ADVISORS LP, P.A.W. CAPITAL CORP, Rock Creek Group, LP, and ARK Investment Management LLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.